1. Market Research
  2. > Pharmaceutical
  3. > Drug Delivery Market Trends
  4. > Global Transdermal Drug Delivery Partnering 2010-2015

Global Transdermal Drug Delivery Partnering 2010-2015

  • July 2015
  • -
  • Currentpartnering
  • -
  • 150 pages

Provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

Transdermal Drug Delivery Partnering 2010-2015 report provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.
Trends in transdermal drug delivery partnering deals
Top transdermal drug delivery deals by value
Deals listed by company A-Z, deal type, stage of development, therapy type

Transdermal Drug Delivery Partnering 2010-2015 provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter transdermal drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 150 links to online copies of actual transdermal drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of transdermal drug delivery dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in transdermal drug delivery dealmaking since 2010.

Chapter 3 is the most popular chapter that includes details of average headline, upfront, milestone and royalty terms.

Chapter 4 provides a review of the leading transdermal drug delivery deals since 2010. Deals are listed by headline value, most active of all biopharma companies and signed by big pharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a comprehensive directory of transdermal drug delivery partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in transdermal drug delivery partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about transdermal drug delivery partnering in the research, development and commercialization of drug delivery technologies and products.

Report scope

Transdermal Drug Delivery Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to transdermal drug delivery trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in transdermal drug delivery dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 150 transdermal drug delivery actual deal records
The leading transdermal deals by value since 2010

In Transdermal Drug Delivery Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Therapy type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Transdermal Drug Delivery Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of transdermal drug delivery deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 150 actual deal records entered into by the world’s biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Transdermal Drug Delivery Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in transdermal drug delivery dealmaking

2.1. Introduction
2.2. Transdermal drug delivery partnering over the years
2.3. Big pharma transdermal drug delivery dealmaking activity
2.4. Transdermal drug delivery partnering by industry type
2.5. Transdermal drug delivery partnering by deal type
2.6. Transdermal drug delivery partnering by disease type

Chapter 3 -Average financial deal terms for transdermal drug delivery partnering

3.1 Transdermal drug delivery deals by headline values
3.2 Transdermal drug delivery upfront payments
3.3 Transdermal drug delivery milestone payments
3.4 Transdermal drug delivery royalty rates

Chapter 4 - Leading transdermal drug delivery deals

4.1. Introduction
4.2. Most active in transdermal drug delivery partnering
4.3. Top transdermal drug delivery deals by value

Chapter 5 - Transdermal drug delivery partnering dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By stage of development
5.5. By industry sector
5.6. By therapy area

Recent report titles from CurrentPartnering
Order Form - Upgrades to subscription access products

Table of figures

Figure 1: Transdermal drug delivery partnering since 2010
Figure 2: Big pharma - top 50 - Transdermal drug delivery deals 2010 to 2015
Figure 3: Big pharma transdermal drug delivery deal frequency - 2010 to 2015
Figure 4: Transdermal drug delivery partnering by industry sector since 2010
Figure 5: Transdermal drug delivery partnering by deal type since 2010
Figure 6: Transdermal drug delivery partnering by disease type since 2010
Figure 7: Transdermal drug delivery deals with a headline value
Figure 8: Transdermal drug delivery deals with an upfront value
Figure 9: Transdermal drug delivery deals with a milestone value
Figure 10: Transdermal drug delivery deals with a royalty rate value
Figure 11: Active transdermal drug delivery dealmaking activity- 2010 to 2015
Figure 12: Top transdermal drug delivery deals by value since 2010

For the full list of companies mentioned in the report, please contact enquiry@currentpartnering.com

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Transdermal Drug Delivery System - Global Market Outlook (2016-2022)

Transdermal Drug Delivery System - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Transdermal Drug Delivery System market is accounted for $16.32 billion in 2015 and is expected to reach $36.58 billion by 2022 growing at a CAGR of 12.2%. Rising ...

Transdermal Drug Delivery Market Analysis & Trends – Technology (Thermal, Iontophoresis, Electroporation, Ultrasound, Electric Current, Microporation, Mechanical Arrays, Radio Frequency), Application - Forecast to 2025

Transdermal Drug Delivery Market Analysis & Trends – Technology (Thermal, Iontophoresis, Electroporation, Ultrasound, Electric Current, Microporation, Mechanical Arrays, Radio Frequency), Application - Forecast to 2025

  • $ 4200
  • Industry report
  • November 2016
  • by Accuray Research LLP

The Global Transdermal Drug Delivery Market is poised to grow at a CAGR of around 11.6% over the next decade to reach approximately $95.57 billion by 2025. Some of the prominent trends that the market ...

Global Transdermal Drug Delivery Systems Market Report 2016

Global Transdermal Drug Delivery Systems Market Report 2016

  • $ 2850
  • Industry report
  • August 2016
  • by 9Dimen Research

2016 Global Transdermal Drug Delivery Systems Report is a professional and in-depth research report on the world's major regional market conditions of the Transdermal Drug Delivery Systems industry, focusing ...

Microneedle Diagnostics

May 2016 $ 3850

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.